3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Esophageal Neoplasms
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Ovarian Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
darolutamide
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Metastatic Hormone-sensitive Prostate Cancer
×
Docetaxel
×
Clear all
NCT02799602
2025-12-04
ARASENS
Bayer
Phase 3
Completed
1,306 enrolled
25 charts
2 FDA